Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine and Paclitaxel in Advanced Breast Cancer
NCT00031876Phase 2Completed
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- May 2000
- Primary completion
- Sep 2004
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine and paclitaxel in breast cancer, sponsored by Swiss Group for Clinical Cancer Research. Primary endpoints: Maximum Tolerated Dose, Objective Response Rate and 4 more. Started May 2000; status: completed.
02
Drugs
capecitabinepaclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00031876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00031876.